Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=clascoterone,pyrilutamide,finasteride

Side-by-side comparison of Clascoterone, Pyrilutamide, Finasteride
Identity
	Clascoterone	Pyrilutamide	Finasteride
Class	Topical androgen-receptor inhibitor (cortexolone 17α-propionate), supplied as a 1% cream	Investigational topical nonsteroidal androgen-receptor antagonist	Small-molecule 5-alpha-reductase type II inhibitor, supplied as oral tablets
Also listed as	Winlevi, CB-03-01, Cortexolone 17α-propionate, Breezula	KX-826, KX826, Pyrilutamide topical	Propecia, Proscar, MK-906
Molecular formula	C24H34O5	Not recorded	C23H36N2O2
Molecular weight	402.5 g/mol	Not recorded	372.55 g/mol
CAS	Not recorded	Not recorded	98319-26-7
PubChem CID	Not recorded	Not recorded	57363
Sequence length	Not recorded	Not recorded	Not recorded
Data caveat	None recorded	None recorded	None recorded
United States regulatory status
Status	FDA-approved drug substance	Investigational	FDA-approved drug substance
FDA application	NDA 213433 (WINLEVI) — approved 26 August 2020	None recorded	NDA 020788 (PROPECIA) — approved 19 December 1997
Compounding	No FDA compounding entry recorded	No FDA compounding entry recorded	No FDA compounding entry recorded
WADA	Not named in this record	Not named in this record	Not named in this record
Research profile
Research purpose	Topical androgen-receptor inhibition for AGA	Topical androgen-receptor blockade	Approved oral androgen-pathway treatment
Proposed mechanism	Blocks androgen receptors in the skin. The hair-loss hypothesis is that local blockade reduces follicular androgen signalling. The acne approval does not establish a hair-growth mechanism.	A nonsteroidal androgen-receptor antagonist applied to the scalp, intended to reduce androgen signalling in follicle cells. The clinical advantage over existing treatments is not established.	Inhibits type II 5-alpha-reductase, reducing conversion of testosterone to dihydrotestosterone. Lower scalp DHT slows follicular miniaturisation in responders.
Human evidence	A Phase 3, vehicle-controlled trial in men with androgenetic alopecia completed in January 2026. No peer-reviewed hair-loss results were indexed at this review.	Phase 2 trials in men and women and a Phase 3 trial in Chinese men are registered; the Phase 2 studies are listed as completed. No approved product.	Randomised trials in men with mild-to-moderate androgenetic alopecia support the approved indication. It is not approved for women.
Evidence tier	Phase 3 trials registered or reported	Phase 3 trials registered or reported	Approved drug product in the United States
Known safety concerns	The acne label lists local skin reactions; the product is applied to the skin, not injected. Systemic androgen suppression is a theoretical concern with any topical antiandrogen; the hair-loss trial was designed to measure it. Hair-loss safety data are not available here as a peer-reviewed report.	Topical androgen-receptor blockade may still produce systemic effects; the trials are designed to measure this. Phase 3 safety data are not available here as a peer-reviewed report. Long-term safety is unknown.	The label carries warnings and precautions, including sexual adverse experiences and effects on prostate-specific antigen. Finasteride is not indicated for women; the label addresses pregnancy risk. This record is not a complete safety profile or a prescribing guide.
Evidence gaps	Peer-reviewed Phase 3 efficacy and safety results in androgenetic alopecia. Whether scalp androgen blockade produces hair benefit without meaningful systemic effects. Long-term safety and durability.	Peer-reviewed Phase 3 efficacy and safety results. Whether topical delivery avoids meaningful systemic androgen blockade. Durability and any regulatory decision.	Reliable prediction of who will respond. The natural history of reported persistent sexual adverse effects after stopping. Long-term outcomes beyond the trial periods.
Head-to-head evidence	No published head-to-head trial against finasteride, minoxidil or pyrilutamide.	No published head-to-head trial against finasteride or minoxidil.	Dutasteride and finasteride have been compared in trials and reviews, but dutasteride is not FDA-approved for hair loss in the United States.
Named pathways	Androgen receptor · DHT signalling · Follicular miniaturisation	Androgen receptor · DHT signalling · Follicular miniaturisation	5-alpha-reductase type II · DHT synthesis · Androgen receptor signalling
Evidence on file
Records	2Open evidence file	2Open evidence file	1Open evidence file
Human-interventional records	1	2	0
Human-observational records	0	0	0
Animal records	0	0	0
In-vitro records	0	0	0
Reviews	0	0	0
Regulatory documents	1	0	1
Earliest indexed	2022	2022	2022
Latest indexed	2026	2024	2022

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.

Overlapping pathways

Named in the mechanism discussion for at least two of these compounds: Androgen receptor · DHT signalling · Follicular miniaturisation.

Shared biology is not shared evidence. No claim of synergy is made here, and overlapping pathways do not mean the compounds have been studied together.